MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application

University of Ulm

Status and phase: Completed; Phase 2

Conditions: Contrast Media Exposition; Chronic Renal Insufficiency; Serum Creatinine Concentration

Treatments: Drug: sodium 2-mercaptoethane sulfonate

Study type: Interventional

Funder types: Other

Identifiers

NCT00223548

A119/2002

Details and patient eligibility

About

The purpose of this study is to determine wether Mesna could prevent contrast-induced nephropathy

Full description

Contrast-induced nephropathy remains a common complication of radiographic precedures. Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure.

The aim of this study is therefore to determine laboratory and clinical benefit of MESNA, as an adjunct to saline hydration, in patients with known renal impairment receiving contrast media.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• stable chronic renal insufficiency
• serum creatinine concentration > 1,5 mg/dl

Exclusion criteria

• Dialyzed patients
• patients with acute renal failure
• received iodinated contrast media within 7 days before study entry
• known allery to Mesna, pregnancy, and administration of dopamine, mannitol or N-acetylcysteine

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind